RT journal article
T1 Therapeutic Approach to Alzheimer's Disease: Current Treatments and New Perspectives
A1 Pardo-Moreno, Teresa
A1 González Acedo, Anabel
A1 Rivas-Domínguez, Antonio
A1 García Morales, Victoria
A1 García Cózar, Francisco José
A1 Ramos-Rodríguez, Juan José
A1 Melguizo-Rodríguez, Lucía
A2 BiomedicinaBiotecnología y Salud Pública
K1 Alzheimer’s disease
K1 dementia
K1 A pathology
K1 tau pathology
K1 pharmacology
K1 drugs
AB Alzheimer's disease (AD) is the most common cause of dementia. The pathophysiology of this disease is characterized by the accumulation of amyloid-beta, leading to the formation of senile plaques, and by the intracellular presence of neurofibrillary tangles based on hyperphosphorylated tau protein. In the therapeutic approach to AD, we can identify three important fronts: the approved drugs currently available for the treatment of the disease, which include aducanumab, donepezil, galantamine, rivastigmine, memantine, and a combination of memantine and donepezil; therapies under investigation that work mainly on A beta pathology and tau pathology, and which include gamma-secretase inhibitors, beta-secretase inhibitors, alpha-secretase modulators, aggregation inhibitors, metal interfering drugs, drugs that enhance A beta clearance, inhibitors of tau protein hyperphosphorylation, tau protein aggregation inhibitors, and drugs that promote the clearance of tau, and finally, other alternative therapies designed to improve lifestyle, thus contributing to the prevention of the disease. Therefore, the aim of this review was to analyze and describe current treatments and possible future alternatives in the therapeutic approach to AD.
PB MDPI
SN 1999-4923
YR 2022
FD 2022-06
LK http://hdl.handle.net/10498/27585
UL http://hdl.handle.net/10498/27585
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 08-nov-2026